SMO mutation predicts the effect of immune checkpoint inhibitor: From NSCLC to multiple cancers

SMO mutation predicts the effect of immune checkpoint inhibitor: From NSCLC to multiple cancers

BackgroundThe emergence of immune checkpoint inhibitors (ICIs) is one of the most promising breakthroughs for the treatment of multiple cancer types, but responses vary. Growing evidence points to a link between developmental signaling pathway-related genes and antitumor immunity, but the associatio...

Full description

Bibliographic Details
Main Authors:	Wenxiang Ji, Xiaomin Niu, Yongfeng Yu, Ziming Li, LinPing Gu, Shun Lu
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-11-01
Series:	Frontiers in Immunology
Subjects:	SMO immune checkpoint inhibitor pan-cancers tumor immune microenvironment (TIME) biomarker
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2022.955800/full

Similar Items

PTPRD/PTPRT mutation as a predictive biomarker of immune checkpoint inhibitors across multiple cancer types
by: Xiaoling Shang, et al.
Published: (2022-09-01)

PBRM1 mutation as a predictive biomarker for immunotherapy in multiple cancers
by: Jiali Dai, et al.
Published: (2023-01-01)

MED12 mutation as a potential predictive biomarker for immune checkpoint inhibitors in pan-cancer
by: Yong Zhou, et al.
Published: (2022-10-01)

Pan‐cancer analysis identifies TERT alterations as predictive biomarkers for immune checkpoint inhibitors treatment
by: Tao Jiang, et al.
Published: (2020-06-01)

Fibroblast growth factor receptor family mutations as a predictive biomarker for immune checkpoint inhibitors and its correlation with tumor immune microenvironment in melanoma
by: Wengang Zhang, et al.
Published: (2022-11-01)

The Evolving Role of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma Treatment
by: Patrizia Leone, et al.
Published: (2021-05-01)

Crosstalk Between the Tumor Microenvironment and Cancer Cells: A Promising Predictive Biomarker for Immune Checkpoint Inhibitors
by: Xiaoying Li, et al.
Published: (2021-10-01)

YAP1 Is a Potential Predictive Molecular Biomarker for Response to SMO Inhibitor in Medulloblastoma Cells
by: Gustavo Alencastro Veiga Cruzeiro, et al.
Published: (2021-12-01)

Research Progress of Efficacy Biomarkers Related to Immune Checkpoint Inhibitors
by: YANG Wenwen, et al.
Published: (2022-05-01)

Targeting T-cell metabolism to boost immune checkpoint inhibitor therapy
by: Haohao Li, et al.
Published: (2022-12-01)

Integrated genomic analysis identifies a genetic mutation model predicting response to immune checkpoint inhibitors in melanoma
by: Junjie Jiang, et al.
Published: (2020-11-01)

Catenin Alpha-2 Mutation Changes the Immune Microenvironment in Lung Adenocarcinoma Patients Receiving Immune Checkpoint Inhibitors
by: Yang Wen, et al.
Published: (2021-06-01)

The Efficacy of Tumor Mutation Burden as a Biomarker of Response to Immune Checkpoint Inhibitors
by: Camille Moeckel, et al.
Published: (2023-04-01)

Intratumoral versus Circulating Lymphoid Cells as Predictive Biomarkers in Lung Cancer Patients Treated with Immune Checkpoint Inhibitors: Is the Easiest Path the Best One?
by: Marta Gascón, et al.
Published: (2020-06-01)

Combined Anti-Cancer Strategies Based on Anti-Checkpoint Inhibitor Antibodies
by: Josée Golay, et al.
Published: (2020-05-01)

Combinatorial Approaches With Checkpoint Inhibitors to Enhance Anti-tumor Immunity
by: Barbara Seliger
Published: (2019-05-01)

Modern Aspects of Immunotherapy with Checkpoint Inhibitors in Melanoma
by: Vera Petrova, et al.
Published: (2020-03-01)

Comprehensive Analysis of the Immune Microenvironment in Checkpoint Inhibitor Pneumonitis
by: Xinqing Lin, et al.
Published: (2022-01-01)

Immune Checkpoint Inhibitors in “Special” NSCLC Populations: A Viable Approach?
by: Giuseppe Bronte, et al.
Published: (2023-08-01)

Mutations Status of Chemokine Signaling Pathway Predict Prognosis of Immune Checkpoint Inhibitors in Colon Adenocarcinoma
by: Anqi Lin, et al.
Published: (2021-10-01)

Dynamic evaluation of blood immune cells predictive of response to immune checkpoint inhibitors in NSCLC by multicolor spectrum flow cytometry
by: Weijie Ma, et al.
Published: (2023-08-01)

Identification and validation of tissue or ctDNA PTPRD phosphatase domain deleterious mutations as prognostic and predictive biomarkers for immune checkpoint inhibitors in non-squamous NSCLC
by: Yiting Sun, et al.
Published: (2021-10-01)

Aging-related biomarker discovery in the era of immune checkpoint inhibitors for cancer patients
by: Abdullah Al-Danakh, et al.
Published: (2024-03-01)

Prognostic Biomarker TP53 Mutations for Immune Checkpoint Blockade Therapy and Its Association With Tumor Microenvironment of Lung Adenocarcinoma
by: Xinqing Lin, et al.
Published: (2020-11-01)

Tumor mutational burden presents limiting effects on predicting the efficacy of immune checkpoint inhibitors and prognostic assessment in adrenocortical carcinoma
by: Fangshi Xu, et al.
Published: (2022-05-01)

Predictive Biomarkers for Immune-Checkpoint Inhibitor Treatment Response in Patients with Hepatocellular Carcinoma
by: Jun Ho Ji, et al.
Published: (2023-04-01)

DNA damage response-related immune activation signature predicts the response to immune checkpoint inhibitors: from gastrointestinal cancer analysis to pan-cancer validation
by: Junya Yan, et al.
Published: (2024-03-01)

A mutation-based gene set predicts survival benefit after immunotherapy across multiple cancers and reveals the immune response landscape
by: Junyu Long, et al.
Published: (2022-02-01)

Checkpoint Inhibitors in Acute Myeloid Leukemia
by: Daniela Damiani, et al.
Published: (2023-06-01)

Challenges of the Immunotherapy: Perspectives and Limitations of the Immune Checkpoint Inhibitor Treatment
by: Paula Dobosz, et al.
Published: (2022-03-01)

ATM Mutations Benefit Bladder Cancer Patients Treated With Immune Checkpoint Inhibitors by Acting on the Tumor Immune Microenvironment
by: Ruibin Yi, et al.
Published: (2020-08-01)

Recent Advance in Biomarkers for Predicting Immune-related Adverse Events Caused by Immune Checkpoint Inhibitors
by: LI Ying, et al.
Published: (2021-04-01)

Repurposing drugs for solid tumor treatment: focus on immune checkpoint inhibitors
by: Qingxu Liu, et al.
Published: (2023-11-01)

Advances in immune checkpoint inhibitors therapy for small cell lung cancer
by: Longhui Li, et al.
Published: (2023-05-01)

CDC25C as a Predictive Biomarker for Immune Checkpoint Inhibitors in Patients With Lung Adenocarcinoma
by: Wengang Zhang, et al.
Published: (2022-04-01)

Combining STAT3-Targeting Agents with Immune Checkpoint Inhibitors in NSCLC
by: Kostas A. Papavassiliou, et al.
Published: (2023-01-01)

The Impact of NOTCH Pathway Alteration on Tumor Microenvironment and Clinical Survival of Immune Checkpoint Inhibitors in NSCLC
by: Xiaohua Li, et al.
Published: (2021-07-01)

B Cell Receptor Signaling Pathway Mutation as Prognosis Predictor of Immune Checkpoint Inhibitors in Lung Adenocarcinoma by Bioinformatic Analysis
by: Lin A, et al.
Published: (2022-09-01)

Immune checkpoint inhibitors in the treatment of hepatocellular carcinoma
by: Zeynep Akbulut, et al.
Published: (2024-04-01)

Biological Factors behind Melanoma Response to Immune Checkpoint Inhibitors
by: Magdalena Olbryt, et al.
Published: (2020-06-01)